JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Pulmatrix Inc

Geschlossen

2.57 1.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.45

Max

2.59

Schlüsselkennzahlen

By Trading Economics

Einkommen

672K

-877K

EPS

-0.24

Gewinnspanne

-60,266.667

Angestellte

2

EBITDA

671K

-877K

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-8.6M

9.3M

Vorheriger Eröffnungskurs

0.99

Vorheriger Schlusskurs

2.57

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2. Feb. 2026, 23:52 UTC

Akquisitionen, Fusionen, Übernahmen

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2. Feb. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2. Feb. 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2. Feb. 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2. Feb. 2026, 23:23 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2. Feb. 2026, 22:57 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2. Feb. 2026, 21:51 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Feb. 2026, 21:49 UTC

Ergebnisse

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2. Feb. 2026, 21:39 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:36 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2. Feb. 2026, 21:34 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2. Feb. 2026, 21:23 UTC

Ergebnisse

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2. Feb. 2026, 21:19 UTC

Ergebnisse

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2. Feb. 2026, 21:17 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:10 UTC

Ergebnisse

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2. Feb. 2026, 21:08 UTC

Ergebnisse

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2. Feb. 2026, 21:07 UTC

Ergebnisse

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Net $608.7M >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Rev $1.41B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q Adj EPS 25c >PLTR

2. Feb. 2026, 21:05 UTC

Ergebnisse

Palantir Technologies 4Q EPS 24c >PLTR

2. Feb. 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
help-icon Live chat